Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07538804 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 294
- Enrollment target
NCT07538804 is a Phase 1 study that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 294 participants.
The verdict
NCT07538804, a Phase 1 study, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 294 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Interventions
- DRUG ANS02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2029-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07538804
The ClinicalTrials.gov registry entry for NCT07538804 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avistone Biotechnology Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ANS02 is the first listed.
NCT07538804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07538804 about?
NCT07538804 is a clinical study titled "A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer". This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
What is the current status of trial NCT07538804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2026-07-10. Estimated completion is 2029-10-30.
What interventions are being tested in trial NCT07538804?
The interventions under investigation include: ANS02 (DRUG).
Who is sponsoring clinical trial NCT07538804?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.